Clinical trials with biological response modifiers in rheumatic diseases
Scheinberg, M.A.
Journal of Rheumatology 15(7): 1056-1057
1988
ISSN/ISBN: 0315-162X PMID: 3050086 Document Number: 324367
Document emailed within 1 workday
Related Documents
Ackermann, R. 1988: Biological response modifiers in renal cancer Progress in Clinical and Biological Research 269: 313-328Ishihara, K. 1989: On the behalf of the Japanese Society of Biological Response Modifiers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Pt 2-1): 906-911
Zlotta, A.R.; Schulman, C.C. 2000: Biological response modifiers for the treatment of superficial bladder tumors European Urology 37(Suppl): 10-15
Kirkpatrick, C.H. 1989: Biological response modifiers. Interferons, interleukins, and transfer factor Annals of Allergy 62(3): 170-176
Okawa, T.; Goto, M.; Kita, M. 1987: Radiotherapy combined with BRM (biological response modifiers) in the treatment of cancer Gan no Rinsho. Japan Journal of Cancer Clinics 33(10): 1253-1256
Muss, H.B. 1988: The role of biological response modifiers in metastatic renal cell carcinoma Seminars in Oncology 15(5 Suppl 5: 30-34
Saito, A. 2001: A putative immunotherapy with biological response modifiers (BRM) against intractable pulmonary tuberculosis Kekkaku: 76(12): 741-747
Irwin, M.M. 1987: Patients receiving biological response modifiers: overview of nursing care Oncology Nursing Forum 14(6 Suppl): 32-37
Koga, H.; Miyazaki, Y.; Kohno, S.; Hara, K. 1994: A drug delivery system and biological response modifiers for the treatment of mycobacterial infection Kekkaku: 69(2): 113-118
Bergmann, L. 1989: Malignant melanoma--prognosis and actual treatment strategies with chemotherapy and biological response modifiers European Journal of Cancer and Clinical Oncology 25(Suppl 3): S31-S36
Talmadge, J.E.; Herberman, R.B. 1986: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers Cancer Treatment Reports 70(1): 171-182
Podzich, M. 1982: Percutaneous therapy of soft tissue rheumatic diseases. Clinical trials of the non-steroid anti-phlogistic agent Rheumon gel ZFA. Zeitschrift für Allgemeinmedizin 58(16): 921-924
Pawłowska, M.łg. 2005: HCV: immune response and its modifiers in clinical development Przeglad Epidemiologiczny 59(2): 519-523
Nio, Y.; Zighelboim, J.; Berek, J.S.; Bonavida, B. 1990: Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers Anticancer Research 10(2a): 441-446
Sodhi, A.; Pai, K. 1992: Studies on the release of interleukin-1 (IL-1), tumor necrosis factor (TNF) and lysozyme from human non-adherent mononuclear cells (nMNC) in vitro after treatment with cisplatin and other biological response modifiers Neoplasma 39(4): 211-217
Rhein, E.; Wenig, A. 1970: Clinical experiences in the treatment of rheumatic and non-rheumatic infectious diseases with an antiphlogistic agents Zeitschrift für Allgemeinmedizin 46(29): 1464-1466
Ortiz, Z.; Shea, B.; Garcia Dieguez, M.; Boers, M.; Tugwell, P.; Boonen, A.; Wells, G. 1999: The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials Journal of Rheumatology 26(1): 210-216
Moiseev, S.V.; Novikov, P.I.; Semenkova, E.N.; Strizhakov, L.A.; Gulyaev, S.V.; Yanushkevich, T.N.; Nikiforova, N.V.; Meshkov, A.D.; Panasyuk, V.V.; Sokorin, Y.D.; Taranova, M.V.; Parfenova, S.A.; Dubrovskaya, L.V.; Zhabina, E.S.; Kuznetsova, E.I.; Lopatina, I.A.; Bulanov, N.M.; Mukhin, N.A. 2013: Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases Terapevticheskii Arkhiv 85(5): 37-43
Sullivan, M.P.; Pullen, D.J.; Crist, W.M.; Brecher, M.; Ramirez, I.; Sabio, H.; Borowitz, M.J.; Head, D.R.; Cerezo, L.; Shuster, J.J. 1990: Clinical and biological heterogeneity of childhood B cell acute lymphocytic leukemia: implications for clinical trials Leukemia 4(1): 6-11
Neumann, W.; Barthel, E.; Tanner, E.; Seidel, K. 1970: Gm-properties in rheumatic diseases with reference to chronic progressive polyarthritis. I. Gm(a) and Gm(x) factors in rheumatic diseases Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 25(7): 308-311